<DOC>
	<DOCNO>NCT01662921</DOCNO>
	<brief_summary>We hypothesize insulin glulisine non-inferior currently prove rapid-acting insulin lispro use basal/bolus regimen treat hyperglycemia patient gestational diabetes mellitus .</brief_summary>
	<brief_title>Comparator Trial Using Insulin Glulisine vs. Insulin Lispro Treatment Gestational Diabetes</brief_title>
	<detailed_description>To date , two rapid-acting insulin analog show safe effective treatment diabetes pregnancy : insulin aspart insulin lispro . The pharmacokinetics pharmacodynamics insulin glulisine unique insulin glulisine may best rapid-acting analog treatment post-prandial hyperglycemia . We believe insulin glulisine evaluate woman gestational diabetes potential efficacy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes , Gestational</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Informed Consent participate clinical trial Pregnant 2030 week gestation Diagnosed gestational diabetes Failed diet therapy ( failed lifestyle modification define 10 % great SMBG value premeal &lt; 90mg/dL post prandial &lt; 120mg/dL Eat least 2 meal per day Pregnant woman &lt; 18 year old Blood pressure &gt; 140/80 mmHg A1C equal great 6.5 % time enrollment Prepregnancy BMI &gt; 40Kg/m squared Evidence fetal anomaly fetal ultrasound Currently use hypoglycemic agent Refusal use insulin meal Inability understand instruction consent participate Pregnant woman history T1DM T2DM Clinical judgment investigator patient inappropriate clinical trial metabolic disorder could interfere result</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>bolus treatment</keyword>
</DOC>